Get started

IONS

Momentum, Growth & Innovation: Updated WatchlistMomentum, Growth & Innovation: Updated Watchlist www.tradingview.com My updated trading watchlist includes a diverse range of companies across various sectors, prominently featuring technology, healthcare, and finance, among others. These companies, currently part of ARK Invest's holdings, are identified as being in a confirmed Stage 2 uptrend, indicating strong bullish trends according to Mark Minervini's methodology. This analysis will highlight key sectors represented, providing a broad understanding of the market dynamics at play. Technology Sector Companies like NASDAQ: NASDAQ:AMD (Advanced Micro Devices Inc) NASDAQ: NASDAQ:MSFT (Microsoft) NASDAQ: NASDAQ:NVDA (NVIDIA Corporation) and NASDAQ: NASDAQ:GOOG (Alphabet) underscore the significant emphasis on technology, particularly in semiconductors, cloud computing, and artificial intelligence. These firms are at the forefront of innovation, driving trends in digital transformation, and represent strong growth opportunities as they capitalize on increasing demand for technology solutions. Healthcare and Biotechnology NASDAQ: NASDAQ:IONS (Ionis Pharmaceuticals) NASDAQ: NASDAQ:RXRX (Recursion Pharmaceuticals Inc) NYSE: NYSE:NET (Cloudflare) and NASDAQ: NASDAQ:VRTX (Vertex Pharmaceuticals Incorporated) highlight the focus on healthcare and biotechnology. This sector benefits from ongoing advancements in medical research, genetic sequencing, and personalized medicine. Companies in this space are pivotal in addressing global health challenges, including new therapies and vaccines, reflecting potential for significant impact and investment returns. Finance and Cryptocurrency With holdings like NYSE: NYSE:ICE (Intercontinental Exchange Inc) NASDAQ: NASDAQ:COIN (Coinbase Global Inc) and AMEX: BITO, there's a clear interest in financial services and the burgeoning field of cryptocurrencies. These selections point to the growing influence of digital assets and blockchain technology in reshaping financial transactions, investment strategies, and asset management. Consumer Discretionary and E-Commerce Companies such as NASDAQ: NASDAQ:AMZN (Amazon.com Inc) NYSE: NYSE:SHOP (Shopify Inc.) and NASDAQ: NASDAQ:MELI (MercadoLibre) represent the e-commerce and consumer discretionary sectors. Their inclusion underscores the continued growth in online retail and digital consumer behaviors, accelerated by global shifts towards online shopping and digital platforms for goods and services. Aerospace and Defense With NYSE: NASDAQ:KTOS (Kratos Defense & Security Solutions Inc) NYSE: NYSE:LHX (L3Harris) and NASDAQ: NASDAQ:AVAV (AeroVironment Inc.) there's an acknowledgment of the importance of aerospace and defense. These companies are involved in cutting-edge technology for national security, space exploration, and unmanned aerial vehicles, sectors expected to see substantial growth due to increased defense spending and interest in space. Conclusion My watchlist reflects a strategic focus on high-growth sectors poised for continued expansion and innovation. By targeting companies within technology, healthcare, finance, consumer discretionary, and aerospace & defense, the list aligns with sectors that not only have strong current performance but also hold future growth potential.
AMEX:ARKK
by JS_TechTrading
IEA’s bullish outlook for electric vehicles “A new clean energy economy is emerging, and it is emerging much faster than many stakeholders, policymakers, industry players, and investors think today” – Fatih Birol, Executive Director, IEA during the Global EV Outlook 2023 press event on 26 April 2023. The International Energy Agency (IEA) published its Global Electric Vehicle Outlook for 2023 on 26 April. Its assessment of the state of the industry is encouraging and its projections for the industry’s growth are exciting. Electrification of road transportation is the disruptive innovation the industry has been waiting for. It appears that the tipping point has been reached. Highlights from 2022, and developments in 2023 Electric vehicle (EV) sales exceeded 10 million in 2022 (see Figure 1). This amounts to 14% of all new cars sold in 2022, up from 9% in 2021, and less than 5% in 2020. This trend has continued at the start of 2023 with over 2.3m EVs sold in the first quarter, 25% more than the same period last year. By the end of the year, sales could hit 14 million with an acceleration expected in the second half of the year1. China remains the dominant market, accounting for around 60% of global electric car sales last year, with Europe and the United States following behind. Nonetheless, there are promising signs of growth in emerging markets such as India, Thailand, and Indonesia where sales of electric cars last year more than tripled compared to 2021. The key tailwinds Policy support for the adoption of electric vehicles has never been stronger and it continues to strengthen. The European Union has set out CO2 standards for cars and vans aligned with 2030 goals set out in the Fit for 55 package. In the US, the Inflation Reduction Act (IRA), and California’s Advanced Clean Cars II rule could accelerate the journey to 50% EV market share by 20302. Given strong support from policymakers and adoption from consumers, innovation in battery manufacturing also appears to have been catalysed. While it is a given that battery chemistries will continue to evolve and greater levels of efficiency will be achieved, developments along the way, such as CATL’s recent condensed battery launch, are noteworthy and encouraging. On 19 April 2023, the Chinese battery manufacturer CATL, among the biggest names in the industry worldwide, unveiled a high-energy density, so-called ‘condensed battery’ at Auto Shanghai. CATL claims that this battery could not only meaningfully increase the range of EV batteries but could also help electrify passenger aircraft. Admittedly, there are multiple unknowns in CATL’s claims, including costs and delivery times, but it highlights how battery manufacturers are focused on achieving new degrees of efficiency. Growing competition and, therefore, more choice for consumers is also facilitating the adoption of EVs. The number of electric car models worldwide exceeded 500 in 2022, more than double compared to 20183. While this is still significantly lower than the number of internal combustion engine (ICE) models on the market, this proliferation of models is increasing competition among original equipment manufacturers (OEMs) which should help bring costs down. Electrification, however, is going beyond passenger cars. In 2022, over half of India’s three-wheeler registrations were electric. Similarly, electric light commercial vehicle sales worldwide increased by more than 90% in 2022 compared to the year before4. Such encouraging growth is also being witnessed in other market segments like electric heavy-duty trucks and buses. The forecast Even in the IEA’s stated policies scenario (STEPS – a conservative scenario which only factors in existing policies), growth of electric vehicles is expected to be strong this decade (see Figure 2). Across the globe, countries are swiftly introducing bans on the sale of new ICE vehicles. Some countries, like Norway, have taken the lead by making this ban effective from 2025. For many other countries, the bans come into effect between 2030 and 2040. Collectively, therefore, it is reasonable to expect a meaningful uptick in EV sales as we progress towards those deadlines. One of the biggest hurdles in EV adoption is the availability of ample public charging infrastructure. Fortunately, charging infrastructure is developing quickly, albeit at different rates in different countries. Overall, however, the IEA have an optimistic view on the number of publicly available charging points worldwide by 2030. A renewed focus on the supply chain According to the IEA, automotive lithium-ion (Li-ion) battery demand increased by about 65% to 550 gigawatt hours (GWh) in 2022, from about 330 GWh in 2021, primarily because of growth in electric passenger car sales. In 2022, about 60% of lithium, 30% of cobalt, and 10% of nickel demand was for EV batteries. Only five years prior, these shares were around 15%, 10% and 2%, respectively. Electric vehicles are not only driving demand for batteries, but also the underlying commodities. For investors, this means a holistic view of automotive and battery value chains is warranted when considering the electrification megatrend. For example, China holds a dominant position in both value chains and its role in terms of where it sits within the value chain is evolving rapidly. China is the biggest manufacturer of batteries worldwide but is also quickly establishing itself in the segment of car companies (OEMs) with the emergence of brands like BYD. But as competition increases, more regulation is introduced, and further innovation happens, supply chains will develop. Some links may get broken while others get formed. All in all, an exciting time to be following this space.
FRED:TOTALSA
by aneekaguptaWTE
On high priority watch list - potential buy opportunityDown trend since January highs after 1st qtr company report. Overall price has dropped over 45%. Potential consolidation with trend reversal. This stock has been on my radar the last 2-3 weeks as I have been evaluating and looking for signs of a reversal before going long. Ratings/analysis are mixed for this stock. I believe there is substantial uncertainty with this stock, but strong upside potential and is probably under valued. There is a high probability I will go long, I am just looking for my entry point.
NASDAQ:IONS
by JLJ002500
Ionis Pharmaceuticals Inc 🧙Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:IONSLong
by unfair_advantage
PREDICTION 3 #IONS - NASDAQ - SELL! UP TO 14% PROFIT!Hi Followers, Welcome to my page, I will be posting 10 charts on USA #STOCK #MARKET this month. #STOCKMARKET Using a Unique Technical Analysis invented by me. Later, if the charts work out, I will talk more about it. As far as our technical Analysis is identifying, there is a big possibility that this company is OVERBOUGHT, which opens a trade opportunity. This could lead allow up to 14% profit and could end in 20 days. About the Company: #IONS - #NASDAQ Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardiometabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardiometabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hypertension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Good Luck and Good Profit
NASDAQ:IONSShort
by UnknownUnicorn5368510